Chaparro et al. 20093939 Chaparro A, Monteverde M, Ibañez J, Adragna M, Lopez L, Briones L, et al. Trasplante renal 1988 - 2008. Med Infant 2009;16:118-25.
|
Not randomized |
Díaz et al. 20084040 Díaz JM, Cabera C, Facundo C, Guirado L, Maderuelo A, Silva I, et al. Evolución de los pacientes trasplantados con riñones procedentes de donantes en asistolia. Actas Fund Puigvert 2008;27:127-30.
|
Not randomized |
Kuypers et al.20054141 Kuypers DR, Malaise J, Claes K, Evenepoel P, Maes B, Coosemans W, et al.; Euro-SPK Study Group. Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005;20:33-9.
|
Kidney/pancreas transplants |
Mehrabi et al. 20074242 Mehrabi A, Mood ZhA, Sadeghi M, Schmied BM, Müller SA, Welsch T, et al. Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation. Nephrol Dial Transplant 2007;22:viii54-viii60. DOI: http://dx.doi.org/10.1093/ndt/gfm651 http://dx.doi.org/10.1093/ndt/gfm651...
|
Not randomized |
Agha et al. 20024343 Agha IA, Rueda J, Alvarez A, Singer GG, Miller BW, Flavin K, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002;73:473-5. DOI: http://dx.doi.org/10.1097/00007890-200202150-00025 http://dx.doi.org/10.1097/00007890-20020...
|
Not randomized |
Moura et al. 20064444 Moura LRR, Pereira MG, Durão M, Tomato EJ, Matos ACC, Wroclawski ER, et al. Imunoglobulina antitimócito como terapia de indução: proteção contra a lesão de isquemia e reperfusão. Einstein (São Paulo) 2006;4:315-20.
|
Not randomized |
Nicoluzzi et al. 20104545 Nicoluzzi JE, Silveira F, Silveira FP, Macri M. Experience with 100 pancreas transplants. Rev Col Bras Cir 2010;37:102-5. DOI:http://dx.doi.org/10.1590/S0100-69912010000200006 http://dx.doi.org/10.1590/S0100-69912010...
|
Pancreas transplants |
Sampaio et al. 20104646 Sampaio ELM, Freitas TVD, Galante NZ, Park SI, Harada KM, Haolla FAB, et al. Terapia de indução com alentuzumabe em receptores de transplante renal. J Bras Nefrol 2010;32:91-9. DOI: http://dx.doi.org/10.1590/S0101-28002010000100015 http://dx.doi.org/10.1590/S0101-28002010...
|
Not randomized |
Sancho et al. 20064747 Sancho A, Gavela E, Crespo JF, Górriz JL, Ávila A, Núñez A, et al. Renal transplantation with positive cross-matching test. Nefrologia 2006;26:261-6.
|
Not randomized |
Laftavi et al. 20114848 Laftavi MR, Patel S, Soliman MR, Alnimri M, Kohli R, Said M, et al. Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy. Transplant Proc 2011;43:466-8. PMID: 21440735 DOI: http://dx.doi.org/10.1016/j.transproceed.2011.01.039 http://dx.doi.org/10.1016/j.transproceed...
|
Not randomized |
Anil Kumar et al. 20084949 Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, et al. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Transpl Immunol 2008;20:32-42. DOI: http://dx.doi.org/10.1016/j.trim.2008.08.005 http://dx.doi.org/10.1016/j.trim.2008.08...
|
Did not assess anti-thymocyte globulin |
Ciancio et al. 20085050 Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation 2008;86:67-74.
|
Did not assess anti-thymocyte globulin |
Buchler et al. 20075151 Büchler M, Caillard S, Barbier S, Thervet E, Toupance O, Mazouz H, et al.; SPIESSER Group. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007;7:2522-31. DOI:http://dx.doi.org/10.1111/j.1600-6143.2007.01976.x http://dx.doi.org/10.1111/j.1600-6143.20...
|
Did not assess anti-thymocyte globulin |
Aoun et al. 20075252 Aoun M, Eschewege P, Hamoudi Y, Beaudreuil S, Duranteau J, Cheisson G, et al. Very early steroid withdrawal in simultaneous pancreas-kidney transplants. Nephrol Dial Transplant 2007;22:899-905. DOI: http://dx.doi.org/10.1093/ndt/gfl660 http://dx.doi.org/10.1093/ndt/gfl660...
|
Kidney/pancreas transplants |
Bogetti et al. 20055353 Bogetti D, Sankary HN, Jarzembowski TM, Manzelli A, Knight PS, Thielke J, et al. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. Clin Transplant 2005;19:507-11. DOI: http://dx.doi.org/10.1111/j.1399-0012.2005.00375.x http://dx.doi.org/10.1111/j.1399-0012.20...
|
Liver transplants |
Hardinger et al. 20055454 Hardinger KL, Bohl DL, Schnitzler MA, Lockwood M, Storch GA, Brennan DC. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation 2005;80:41-6. PMID: 16003231 DOI:http://dx.doi.org/10.1097/01.TP.0000162980.68628.5A http://dx.doi.org/10.1097/01.TP.00001629...
|
Did not assess anti-thymocyte globulin |
Lo et al. 20045555 Lo A, Egidi MF, Gaber LW, Shokouh-Amiri MH, Nazakatgoo N, Fisher JS, et al. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. Clin Transplant 2004;18:53-61. DOI: http://dx.doi.org/10.1111/j.1399-0012.2004.00116.x http://dx.doi.org/10.1111/j.1399-0012.20...
|
Did not assess anti-thymocyte globulin |
Stegall et al. 20035656 Stegall MD, Larson TS, Prieto M, Gloor J, Textor S, Nyberg S, et al. Kidney transplantation without calcineurin inhibitors using sirolimus. Transplant Proc 2003;35:125S-7S. DOI: http://dx.doi.org/10.1016/S0041-1345(03)00226-4 http://dx.doi.org/10.1016/S0041-1345(03)...
|
Did not assess anti-thymocyte globulin |
Kim et al. 20125757 Kim JM, Jang HR, Ko JS, Kwon CH, Kwak MS, Hur WS, et al. Comparison between thymoglobulin and ATGAM as an induction agent in adult kidney transplantation: a single-center experience. Transplant Proc 2012;44:171-4. DOI: http://dx.doi.org/10.1016/j.transproceed.2011.11.061 http://dx.doi.org/10.1016/j.transproceed...
|
Not randomized |
LaMattina et al. 20125858 LaMattina JC, Mezrich JD, Hofmann RM, Foley DP, D'Alessandro AM, Sollinger HW, et al. Alemtuzumab as compared to alternative contemporary induction regimens. Transpl Int 2012;25:518-26. DOI: http://dx.doi.org/10.1111/j.1432-2277.2012.01448.x http://dx.doi.org/10.1111/j.1432-2277.20...
|
Not randomized |
Ciancio et al. 20115959 Ciancio G, Gaynor JJ, Sageshima J, Guerra G, Zarak A, Roth D, et al. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. Transplantation 2011;92:1348-57. PMID: 22027927 DOI: http://dx.doi.org/10.1097/TP.0b013e3182384b21 http://dx.doi.org/10.1097/TP.0b013e31823...
|
Did not assess anti-thymocyte globulin |
Hourmant et al. 19946060 Hourmant M, Le Mauff B, Cantarovich D, Dantal J, Baatard R, Denis M, et al. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. II. Results after a second kidney transplantation. Transplantation 1994;57:204-7. PMID: 8310508 DOI:http://dx.doi.org/10.1097/00007890-199401001-00008 http://dx.doi.org/10.1097/00007890-19940...
|
Not randomized |
Martin et al. 20116161 Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, et al. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal. Pharmacotherapy 2011;31:566-73. DOI: http://dx.doi.org/10.1592/phco.31.6.566 http://dx.doi.org/10.1592/phco.31.6.566...
|
Not randomized |
Thielke et al. 20056262 Thielke J, DeChristopher PJ, Sankary H, Oberholzer J, Testa G, Benedetti E. Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis. Transplant Proc 2005;37:643-4. PMID: 15848486 DOI:http://dx.doi.org/10.1016/j.transproceed.2004.12.063 http://dx.doi.org/10.1016/j.transproceed...
|
Not randomized |
Ulrich et al. 20116363 Ulrich F, Niedzwiecki S, Pascher A, Kohler S, Weiss S, Fikatas P, et al. Long-term outcome of ATG vs. Basiliximab induction. Eur J Clin Invest 2011;41:971-8. DOI: http://dx.doi.org/10.1111/j.1365-2362.2011.02490.x http://dx.doi.org/10.1111/j.1365-2362.20...
|
Not randomized |